# Bibliography

## Bibliography

<a id="cite1"></a> [1] Learning from the Letters: FDA Complete Response Letter Trends (2020–2024) and What They Mean for Sponsors

- Published:July 14, 2025
- URL: <https://www.auriacompliance.com/gmp-blog/learning-from-the-letters-fda-complete-response-letter-trends-20202024-and-what-they-mean-for-sponsors>
- Access: Auriacompliance regulatory insights blog
- Status: ✓ Active



<a id="cite2"></a> [2] Investigational New Drug Applications: A 1‑Year Pilot Study on Rates and Reasons for Clinical Hold

- Published: 2016 (Journal of Investigative Medicine)
- URL: <https://pubmed.ncbi.nlm.nih.gov/26911627>



<a id="cite3"></a> [3] What is a Complete Response Letter?

- Publisher: Avalere Health
- Date: November 30, 2023
- URL: <https://avalere.com/insights/what-is-a-complete-response-letter>
- Notes: Explains CRLs and notes CRL frequency in the 2018–2022 PDUFA cycle.
- Status: ✓ Active



<a id="cite4"></a> [4] Multiplier AI Medical Writing Platform – Case Study of AI‑Assisted Regulatory Authoring

- Published:2025
- URL: <https://multiplierai.co/medical-writing/>
- Access: Multiplier AI product case‑study page
- Status: ✓ Active



<a id="cite5"></a> [5] Axtria Rapid CSR: AI‑Automated Clinical Study Report Authoring

- Published: March 3, 2025
- URL: <https://analyticsindiamag.com/ai-highlights/revolutionise-your-research-with-axtria-rapid-csr-for-faster-more-accurate-clinical-study-reports/>
- Access: Analytics India Magazine news article
- Status: ✓ Active



<a id="cite6"></a> [6] Life Science GenAI Software for Medical Writing | CoAuthor™

- Publisher: Certara
- Date: Accessed January 5, 2026
- URL: <https://www.certara.com/coauthor/>
- Notes: Certara product page describing CoAuthor features and claimed efficiency gains.
- Status: ✓ Active

<a id="cite7"></a> [7] Dr.Evidence: AI Labeling & Regulatory Intelligence Platform

- Publisher: Dr.Evidence
- Date: Accessed January 5, 2026
- URL: <https://www.drevidence.com/>
- Notes: Product page describing access to large regulatory/labeling document corpora and landscape intelligence.
- Status: ✓ Active

<a id="cite8"></a> [8] How AI is transforming global regulatory processes

- Publisher: IQVIA
- Date: September 24, 2025
- URL: <https://www.iqvia.com/blogs/2025/09/how-ai-is-transforming-global-regulatory-processes>
- Notes: Overview of AI use in regulatory intelligence, comparisons, and pattern detection across markets.
- Status: ✓ Active

<a id="cite9"></a> [9] Transformative roles of digital twins from drug discovery to continuous manufacturing: biopharma/biotech and biopharmaceutical perspectives

- Publisher: International Journal of Pharmaceutics: X (Elsevier)
- Date: 2025
- URL: <https://www.sciencedirect.com/science/article/pii/S2590156725000945>
- Notes: Open-access review of digital twin applications in pharma/biopharma, including manufacturing optimization and predictive analytics.
- Status: ✓ Active

<a id="cite10"></a> [10] Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products

- Publisher: U.S. Food and Drug Administration (FDA)
- Date: January 6, 2025
- URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological>
- Status: ✓ Active

<a id="cite11"></a> [11] Governance Premiums and Investor Valuation Adjustments

- Published: March 2006
- URL: <https://www.ifc.org/content/dam/ifc/doc/mgrt/irresistiblecase4cg.pdf>
- Access: International Finance Corporation (IFC) corporate governance report
- Status: ✓ Active



<a id="cite12"></a> [12] AI | NEXT Medical Writing Automation

- Publisher: Trilogy Writing & Consulting (Indegene)
- Date: Accessed January 5, 2026
- URL: <https://trilogywriting.com/ai/>
- Notes: Platform overview for AI-supported medical writing automation and transparency/traceability framing.
- Status: ✓ Active

<a id="cite13"></a> [13] Modernizing Pharma Governance for Faster Portfolio Decisions

- Published: 2025
- URL: <https://www.worldpharmatoday.com/techno-trends/modernizing-governance-structures-for-faster-portfolio-decisions/>
- Access: World Pharma Today technology trends article
- Status: ✓ Active



<a id="cite14"></a> [14] Project Management for the Biopharma/biotech Industry (Guidance Document)

- Publisher: ISPE (International Society for Biopharma/biotech Engineering)
- Date: Accessed January 5, 2026
- URL: <https://ispe.org/publications/guidance-documents/project-management-biopharma/biotech-industry>
- Notes: Industry guidance on pharma project management tools/techniques and integrating compliance into project delivery.
- Status: ✓ Active

<a id="cite15"></a> [15] Quality Control Process for Regulatory Submissions: Cross‑Functional Teams and Tiered Reviews

- Published: 2025
- URL: <https://www.pharmaregulator.in/quality-control-process-regulatory-submissions>
- Access: PharmaRegulatory white paper
- Status: ✓ Active



<a id="cite16"></a> [16] RACI Matrix: Clarifying Roles and Eliminating Ambiguity

- Published: April 2025
- URL: <https://plprojects.co.uk/raci-matrix-project-management/>
- Access: PL Projects project‑management article
- Status: ✓ Active



<a id="cite17"></a> [17] Clear Roles Increase Project Success: Insights from the Project Management Institute

- Published: 2024
- URL: <https://plprojects.co.uk/raci-benefits-and-pmi-research>
- Access: PL Projects article citing Project Management Institute research
- Status: ✓ Active



<a id="cite18"></a> [18] Critical Path Method: Managing Project Duration and Constraints

- Published: 2025
- URL: <https://www.teamgantt.com/critical-path-method-guide>
- Access: TeamGantt project‑management guide
- Status: ✓ Active



<a id="cite19"></a> [19] Cross‑Functional Review: Peer, QC, and Functional Lead Approvals

- Published: 2025
- URL: <https://www.pharmaregulator.in/quality-control-process-regulatory-submissions>
- Access: PharmaRegulatory white paper
- Status: ✓ Active



<a id="cite20"></a> [20] Standardized Documentation and Error Reduction through Tiered QA

- Published: 2024
- URL: <https://docsie.io/blog/quality-control-documentation-best-practices>
- Access: Docsie documentation best‑practices article
- Status: ✓ Active



<a id="cite21"></a> [21] Target Product Profile: Strategic Blueprint Aligning Development and Labeling

- Published: 2024
- URL: <https://intuitionlabs.ai/articles/target-product-profile-strategy>
- Access: Intuition Labs article
- Status: ✓ Active




<a id="cite22"></a> [22] Biopharma/biotech Portfolio Management: A Complete Primer (Risk Appetite, Prioritization, and Governance)

- Published: May 21, 2023
- URL: <https://www.planview.com/resources/articles/biopharma/biotech-portfolio-management-a-complete-primer/>
- Access: Planview resources
- Status: ✓ Active


<a id="cite23"></a> [23] A Strategic Investor's Guide to Biopharma/biotech Portfolio Risk Assessment

- Published: December 10, 2025
- URL: <https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/>
- Access: DrugPatentWatch industry analysis
- Status: ✓ Active

<a id="cite24"></a> [24] Clinical Holds for Cell and Gene Therapy Trials: Duration and Causes

- Published: 2023
- URL: <https://www.celltherapyjournal.org/article/S2329-0501(23)00041-5/fulltext>
- Access: Molecular Therapy – Methods & Clinical Development (open‑access article)
- Status: ✓ Active



<a id="cite25"></a> [25] Multi‑Dimensional Due Diligence in Life Sciences Transactions

- Published: October 13, 2025
- URL: <https://www.gsquaredcfo.com/blog/life-sciences-due-diligence>
- Access: G‑Squared Partners due‑diligence blog
- Status: ✓ Active



<a id="cite26"></a> [26] FDA Clinical Holds: When and Why

- Published: 2024
- URL: <https://gardner.law/insights/clinical-holds-when-and-why>
- Access: Gardner Law regulatory insights blog
- Status: ✓ Active




<a id="cite27"></a> [27] What Every Pharma Executive Should Know About Regulatory Intelligence

- Published: July 23, 2025
- URL: <https://ioni.ai/post/what-every-pharma-executive-should-know-about-regulatory-intelligence>
- Access: IONI AI industry analysis
- Status: ✓ Active


<a id="cite28"></a> [28] The 176 Guidance Documents FDA is Currently Working On

- Published: January 28, 2025
- URL: <https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/>
- Access: AgencyIQ regulatory intelligence
- Status: ✓ Active


<a id="cite29"></a> [29] Transforming Clinical Trials to Improve Pharma ROI (Operational Delays and Efficiency Levers)

- Published: August 4, 2020
- URL: <https://www.iconplc.com/insights/transforming-trials>
- Access: ICON PLC insights
- Status: ✓ Active


<a id="cite30"></a> [30] Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment

- Published: August 24, 2018
- URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment>
- Access: FDA guidance document
- Status: ✓ Active


<a id="cite31"></a> [31] FDA’s Risk-Based Approach to Inspections

- Published: January 17, 2024
- URL: <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-basics/fdas-risk-based-approach-inspections>
- Access: FDA inspection basics
- Status: ✓ Active

<a id="cite32"></a> [32] Manufacturing Control Strategy and CMC Deficiencies

- Published: 2025
- URL: <https://synergbiopharma.com/process-control-elements>
- Access: Syner‑G BioPharma Group blog post
- Status: ✓ Active




<a id="cite33"></a> [33] Clinical Data Integration Platforms and EDC Ecosystems (Medidata / Industry Overview)

- Published: (undated; accessed 2026-01-05)
- URL: <https://www.medidata.com/en/clinical-trial-management/>
- Access: Medidata product overview (context)
- Status: ✓ Active


<a id="cite34"></a> [34] Digitalizing Pharma Control Strategies: A Roadmap

- Published: December 22, 2024
- URL: <https://www.valgenesis.com/blog/digitalizing-pharma-control-strategies-a-roadmap>
- Access: ValGenesis regulatory blog (context)
- Status: ✓ Active

<a id="cite35"></a> [35] Financial Impact of a Day of Delay in Drug Development

- Published: August 2024
- Access: Tufts Center for the Study of Drug Development (CSDD) white paper
- Status: ✓ Active



<a id="cite36"></a> [36] CBER–CDER Pre‑IND Meeting Guidance: Generic Responses

- Published: December 2023
- URL: <https://seed.nih.gov/sites/default/files/2023-12/Pre-IND-Meetings-FDA.pdf>
- Access: NIH SEED and FDA collaborative guidance (PDF)
- Status: ✓ Active



<a id="cite37"></a> [37] Ambiguity in Pre‑IND Meeting Feedback

- Published: December 2023
- URL: <https://seed.nih.gov/sites/default/files/2023-12/Pre-IND-Meetings-FDA.pdf>
- Access: NIH SEED and FDA collaborative guidance (PDF)
- Status: ✓ Active



<a id="cite38"></a> [38] Cost of Poor Quality and Form 483 Observations

- Published: November 8, 2024
- URL: <https://redica.com/how-much-can-poor-quality-cost-you/>
- Access: Redica Systems blog post
- Status: ✓ Active




<a id="cite39"></a> [39] CDER Quality Management Maturity (QMM)

- Published: December 12, 2025
- URL: <https://www.fda.gov/drugs/biopharma/biotech-quality-resources/cder-quality-management-maturity>
- Access: FDA QMM program overview
- Status: ✓ Active


<a id="cite40"></a> [40] CBER SOPP 8410: Determining When Pre-License/Pre-Approval Inspections Are Needed and When They May Be Waived

- Published: January 6, 2020
- URL: <https://www.fda.gov/media/108969/download>
- Access: FDA CBER SOPP (PDF)
- Status: ✓ Active

<a id="cite41"></a> [41] Investor Valuation Drivers: Governance vs. Luck

- Published: October 13, 2025
- URL: <https://www.gsquaredcfo.com/blog/life-sciences-due-diligence>
- Access: G‑Squared Partners due‑diligence blog
- Status: ✓ Active



<a id="cite42"></a> [42] Distinguishing Governance Quality from Luck in Investor Due Diligence

- Published: 2025
- URL: <https://www.gsquaredcfo.com/blog/life-sciences-due-diligence>
- Access: G‑Squared Partners due‑diligence blog
- Status: ✓ Active



<a id="cite43"></a> [43] Measuring AI ROI in Drug Discovery: Key Metrics & Outcomes

- Published: January 3 2026
- URL: <https://intuitionlabs.ai/articles/measuring-ai-roi-drug-discovery>
- Access: Intuition Labs Research
- Status: ✓ Active



<a id="cite44"></a> [44] ROI of AI in Regulatory: Case Studies from Biotech & Small Pharma

- Published: October 12 2025
- URL: <https://numantratech.com/roi-of-ai-in-regulatory-case-studies-from-biotech-small-pharma/>
- Access: Numantra Tech Research
- Status: ✓ Active



<a id="cite45"></a> [45] Framework to Identify Innovative Sources of Value Creation

- Published: May 18 2025
- URL: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12130853/>
- Access: PubMed Central
- Status: ✓ Active



<a id="cite46"></a> [46] FDA Proposes Framework to Advance Credibility of AI Models Used in Drug and Biological Products

- Published:May 31, 2025
- URL: <https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-products>
- Access: FDA Official Press Announcement
- Status: ✓ Active



<a id="cite47"></a> [47] FDA Proposes Framework to Assess AI Model Output Credibility to Support Regulatory Decision- Making

- Published:January 28, 2025
- URL: <https://www.cmhealthlaw.com/2025/01/fda-proposes-framework-to-assess-ai-model-output-credibility-to-support-regulatory-decision->
- Access: CM Health Law Analysis (Third-party Commentary)
- Status: ✓ Active



<a id="cite48"></a> [48] Considerations for the Use of Artificial Intelligence - FDA Official Guidance

- Published: May 31, 2025 (Draft Guidance FDA-2024-D-4689)
- URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regu>
- Access: FDA Official Guidance Document Library
- Status: ✓ Active



<a id="cite49"></a> [49] Regulating the Use of AI in Drug Development: Legal Challenges and Compliance Strategies

- Published:August 19, 2025
- URL: <https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/>
- Access: FDA Law Institute (FDLI)
- Status: ✓ Active



<a id="cite50"></a> [50] FDA Unveils Long-Awaited Guidance on AI Use to Support Drug and Biologic Development

- Published:January 20, 2025
- URL: <https://www.hoganlovells.com/en/publications/fda-unveils-longawaited-guidance-on-ai-use-to-support-drug-and-biologic-development>
- Access: Hogan Lovells Law Firm Analysis
- Status: ✓ Active



<a id="cite51"></a> [51] Deciphering FDA's 7-Step Framework For AI-Driven Decision-Making

- Published: February 26, 2025
- URL: <https://www.bioprocessonline.com/doc/deciphering-fda-s-step-framework-for-ai-driven-decision-making-0001>
- Access: BioProcess Online
- Status: ✓ Active



<a id="cite52"></a> [52] FDA's AI Guidance: 7-Step Credibility Framework Explained

- Published: October 19, 2018 (Updated 2025)
- URL: <https://intuitionlabs.ai/articles/fda-ai-drug-development-guidance>
- Access: Intuition Labs
- Status: ✓ Active



<a id="cite53"></a> [53] Regulatory Strategy Reimagined: Three Trends Accelerating Drug Development

- Published: November 11, 2025
- URL: <https://www.drugdiscoverytrends.com/regulatory-strategy-reimagined-three-trends-accelerating-drug-development/>
- Access: Drug Discovery Trends
- Status: ✓ Active



<a id="cite54"></a> [54] eCTD Resources - FDA Electronic Submission Standards

- Published: September 15, 2024
- URL: <https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-resources>
- Access: FDA eCTD Resources Library
- Status: ✓ Active



<a id="cite55"></a> [55] The 176 guidance documents that FDA is currently working on affecting the life sciences industry

- Published: January 29, 2025
- URL: <https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/>
- Access: AgencyIQ blog
- Status: ✓ Active


<a id="cite56"></a> [56] The 8 FDA Regulatory Trends Shaping 2026 and Beyond

- Published: December 8, 2025
- URL: <https://lumanity.com/perspectives/the-8-fda-regulatory-trends-shaping-2026-and-beyond/>
- Access: Lumanity Regulatory Intelligence
- Status: ✓ Active



<a id="cite57"></a> [57] The 176 Guidance Documents FDA is Currently Working On

- Published: January 28, 2025
- URL: <https://www.agencyiq.com/blog/the-176-guidance-documents-that-fda-is-currently-working-on-affecting-the-life-sciences-industry/>
- Access: AgencyIQ Industry Analysis
- Status: ✓ Active



<a id="cite58"></a> [58] PDUFA VIII: Fiscal Years 2028-2032 - FDA Reauthorization

- Published: December 21, 2025
- URL: <https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-viii-fiscal-years-2028-2032>
- Access: FDA Official Reauthorization Page
- Status: ✓ Active



<a id="cite59"></a> [59] FDA's New Module 1 is a Bridge to eCTD 4

- Published: May 1, 2025
- URL: <https://www.certara.com/blog/fdas-new-module-1-is-a-bridge-to-ectd-4/>
- Access: Certara Regulatory Blog
- Status: ✓ Active



<a id="cite60"></a> [60] eCTD Submission Standards for eCTD v4.0 and Regional M1

- Published: October 19, 2025
- URL: <https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1>
- Access: FDA eCTD v4.0 Implementation Standards
- Status: ✓ Active



<a id="cite61"></a> [61] Future of AI Regulation in Drug Development: A Comparative Analysis

- Published: July 10, 2025
- URL: <https://academic.oup.com/jlb/article/12/2/lsaf028/8316994>
- Access: Oxford Journal of Legal Biomedicine
- Status: ✓ Active



<a id="cite62"></a> [62] Reimagining Drug Regulation in the Age of AI: A Framework for the AI-Enabled Ecosystem in Therapeutics

- Published:October 15, 2025
- URL: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12571717/>
- Access: PubMed Central / Journal of Legal Biomedicine
- Status: ✓ Active



<a id="cite63"></a> [63] The eCTD Backbone Files Specification for Module 1

- Published: October 31, 2012 (Updated versions ongoing)
- URL: <https://www.fda.gov/media/159382/download>
- Access: FDA PDF Download
- Status: ✓ Active



<a id="cite64"></a> [64] AI Medical Devices: FDA Draft Guidance, TPLC & PCCP Guide 2025

- Published: October 16, 2025
- URL: <https://www.complizen.ai/post/fda-ai-medical-device-regulation-2025>
- Access: Complizen Regulatory Intelligence
- Status: ✓ Active



<a id="cite65"></a> [65] An Example AI Readiness in Pharma Assessment Framework

- Published: July 9, 2025
- URL: <https://solutionsreview.com/an-example-ai-readiness-in-pharma-assessment-framework/>
- Access: Solutions Review Platform
- Status: ✓ Active



<a id="cite66"></a> [66] FDA Issues Draft Guidance Documents on Artificial Intelligence for Medical Devices

- Published: January 13, 2025
- URL: <https://www.sternekessler.com/news-insights/client-alerts/fda-issues-draft-guidance-documents-on-artificial-intelligence-for-med>
- Access: Sterne Kessler Law Firm Alert
- Status: ✓ Active



<a id="cite67"></a> [67] What Does the FDA Say About the Use of AI in Clinical Trials?

- Published: October 21, 2025
- URL: <https://trialx.com/what-does-the-fda-say-about-the-use-of-ai-in-clinical-trials-a-summary/>
- Access: TrialX Clinical Trial Platform
- Status: ✓ Active



<a id="cite68"></a> [68] AI for Drug Development: Ensure FDA Compliance

- Published: June 24, 2025
- URL: <https://domino.ai/blog/ai-for-drug-development-a-roadmap-for-fda-compliance>
- Access: Domino Data Lab
- Status: ✓ Active



<a id="cite69"></a> [69] Evaluating Transparency in AI/ML Model Characteristics for FDA Submissions

- Published: November 16, 2025
- URL: <https://www.nature.com/articles/s41746-025-02052-9>
- Access: Nature Digital Medicine
- Status: ✓ Active



<a id="cite70"></a> [70] Building a Comprehensive AI Governance Framework in Life Sciences

- Published: November 10, 2025
- URL: <https://www.paulhastings.com/insights/client-alerts/building-a-comprehensive-ai-governance-framework-in-life-sciences>
- Access: Paul Hastings LLP
- Status: ✓ Active



<a id="cite71"></a> [71] AI in Drug Development: FDA Draft Guidance Addresses Product Development

- Published: January   6,  2025
- URL: <https://www.raps.org/news-and-articles/news-articles/2025/1/ai-in-drug-development-fda-draft-guidance-addresse>
- Access: Regulatory Affairs Professionals Society (RAPS)
- Status: ✓ Active



<a id="cite72"></a> [72] Artificial Intelligence in Software as a Medical Device - FDA

- Published: March 24, 2025
- URL: <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device>
- Access: FDA AI in SaMD Resource Hub
- Status: ✓ Active



<a id="cite73"></a> [73] Episode 2: AI Regulations in Healthcare, Pharma, and Biotech

- Published: May 5, 2024
- URL: <https://www.modelop.com/good-decisions-series/good-decisions-ep2>
- Access: ModelOp Podcast Series
- Status: ✓ Active



<a id="cite74"></a> [74] A Strategic Investor's Guide to Biopharma/biotech Portfolio Risk Assessment

- Published: December 10, 2025
- URL: <https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/>
- Access: Drug Patent Watch
- Status: ✓ Active



<a id="cite75"></a> [75] Pharma Portfolio Management: Strategies for Success

- Published: December 31, 2023
- URL: <https://pipharmaintelligence.com/blog/64>
- Access: PI Pharma Intelligence
- Status: ✓ Active



<a id="cite76"></a> [76] Transforming Clinical Trials to Improve Pharma ROI

- Published: August 4, 2020
- URL: <https://www.iconplc.com/insights/transforming-trials>
- Access: ICON PLC
- Status: ✓ Active



<a id="cite77"></a> [77] Biotech Asset Valuation Methods: A Practitioner's Guide

- Published: 2024
- URL: <https://www.analysisgroup.com/globalassets/insights/publishing/2024-biotech-asset-valuation-methods.pdf>
- Access: Analysis Group PDF
- Status: ✓ Active



<a id="cite78"></a> [78] Measuring the Return from Biopharma/biotech Innovation 2024

- Published: February 24, 2025
- URL: <https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-biopharma/biotech-innovation.htm>
- Access: Deloitte Life Sciences
- Status: ✓ Active



<a id="cite79"></a> [79] Biopharma/biotech Portfolio Management: A Complete Primer

- Published: May 21, 2023
- URL: <https://www.planview.com/resources/articles/biopharma/biotech-portfolio-management-a-complete-primer/>
- Access: Planview Resources
- Status: ✓ Active



<a id="cite80"></a> [80] Transition Acceleration Framework: A New Approach for Private Capital

- Published: September 10, 2025
- URL: <https://intelligence.generatecapital.com/transition-acceleration-framework/>
- Access: Generate Capital Research
- Status: ✓ Active



<a id="cite81"></a> [81] Microsoft Copilot Adoption: 12 vs 24-Week Rollouts for Pharma

- Published: December 30, 2025
- URL: <https://www.adoptify.ai/blogs/microsoft-copilot-adoption-12-vs-24-week-rollouts-for-pharma/>
- Access: Adoptify AI Implementation
- Status: ✓ Active



<a id="cite82"></a> [82] Regulatory Governance and the Evolution of Lean Regulators

- Published: October 18, 2025
- URL: <https://journalwjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0919.pdf>
- Access: World Journal of Biological Pharmacy & Health Sciences
- Status: ✓ Active



<a id="cite83"></a> [83] Driving Strategic Excellence in Biopharma/biotech: A Manager's Guide

- Published: March 16, 2025
- URL: <https://kanboapp.com/en/teams/management-teams/driving-strategic-excellence-in-biopharma/biotech-a-managers-guide-to-harnessing-fr>
- Access: Kanbo App Blog
- Status: ✓ Active



<a id="cite84"></a> [84] Governance Models for RA-QA Alignment in FDA-Regulated Companies

- Published: December 18, 2025
- URL: <https://www.pharmaregulatory.in/governance-models-for-ra-qa-alignment-in-fda-regulated-companies/>
- Access: Pharma Regulatory India
- Status: ✓ Active



<a id="cite85"></a> [85] Biopharma/biotech Competitive Intelligence: 2026 Guide

- Published: December 31, 2025
- URL: <https://www.biopharmavantage.com/competitive-intelligence>
- Access: BioPharma Vantage
- Status: ✓ Active



<a id="cite86"></a> [86] The Role of Implementation Science in Achieving Scale and Adoption

- Published: July 22, 2025
- URL: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12395526/>
- Access: PubMed Central
- Status: ✓ Active



<a id="cite87"></a> [87] FDA Regulatory Strategy, Federal Policy Development and Advocacy

- Published: September 16, 2025
- URL: <https://leavittpartners.com/fda-regulatory-strategy-federal-policy-development-and-advocacy-and-alliance-building/>
- Access: Leavitt Partners
- Status: ✓ Active



<a id="cite88"></a> [88] Top Three Change Management Tips for Rolling Out AI Insights

- Published: May 19, 2025
- URL: <https://marketlogicsoftware.com/blog/top-three-change-management-tips-for-rolling-out-ai-insights/>
- Access: Market Logic Software
- Status: ✓ Active



<a id="cite89"></a> [89] Navigating FDA Regulatory Changes: Policy Shifts & Future Oversight

- Published: June 22, 2025
- URL: <https://www.clinicalleader.com/doc/navigating-fda-regulatory-changes-policy-shifts-deregulation-restructuring-and-future-oversig>
- Access: Clinical Leader Magazine
- Status: ✓ Active



<a id="cite90"></a> [90] Change Management: The Hidden Hurdle of AI Adoption

- Published: September 15, 2024
- URL: <https://www.artosai.com/blog/change-management-the-hidden-hurdle-of-ai-adoption>
- Access: Artos AI Blog
- Status: ✓ Active



<a id="cite91"></a> [91] IT Operating Plan - FDA

- Published: January 16, 2025
- URL: <https://www.fda.gov/media/185225/download>
- Access: FDA PDF Download
- Status: ✓ Active



<a id="cite92"></a> [92] What Every Pharma Executive Should Know About Regulatory Intelligence

- Published: July 23, 2025
- URL: <https://ioni.ai/post/what-every-pharma-executive-should-know-about-regulatory-intelligence>
- Access: IONI AI
- Status: ✓ Active



<a id="cite93"></a> [93] Medicare Drug Price Negotiation Program: Final Guidance

- Published: October 1, 2024
- URL: <https://www.cms.gov/files/document/medicare-drug-price-negotiation-final-guidance-ipay-2027-and-manufacturer-effectuation-mfp-20>
- Access: CMS PDF Download
- Status: ✓ Active



<a id="cite94"></a> [94] A Strategic Investor’s Guide to Biopharma/biotech Portfolio Risk Assessment

- Published: December 11, 2025
- URL: <https://www.drugpatentwatch.com/blog/a-strategic-investors-guide-to-biopharma/biotech-portfolio-risk-assessment/>
- Access: DrugPatentWatch blog
- Status: ✓ Active



<a id="cite95"></a> [95] Governance Models for RA–QA Alignment in FDA‑Regulated Companies

- Published: December 19, 2025
- URL: <https://www.pharmaregulatory.in/governance-models-for-ra-qa-alignment-in-fda-regulated-companies/>
- Access: PharmaRegulatory.in – India's Regulatory Knowledge Hub
- Status: ✓ Active



<a id="cite96"></a> [96] FDA Oversight: Understanding the Regulation of Health AI Tools

- Published: November 10, 2025
- URL: <https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/>
- Access: Bipartisan Policy Center issue brief
- Status: ✓ Active




---